Suppliers / Alchymars ICM SM

Alchymars ICM SM

India Updated 9 July 2026

Alchymars ICM SM is an API manufacturer based in India. It holds 4 active US drug master files across a filed portfolio of 4 molecules. Its most recent recorded inspection, by US FDA, closed on 4 December 2025 as OAI. Customs aggregates show $1.0M of exports covering 6 molecules to 2 destinations in 2025.

4
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 4 December 2025 OAI US FDA
  • 22 November 2022 VAI US FDA
  • 19 October 2018 OAI US FDA
  • 15 September 2017 OAI US FDA
  • 6 February 2015 VAI US FDA
  • 2 April 2012 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Chengalpattu District, India 3005216842

What they file, and where

Molecule Regulators Docs
Warfarin SFDA (Saudi Arabia), US FDA 2
Atovaquone US FDA 1
Clindamycin US FDA 1
Risedronic Acid US FDA 1

Also appears on these molecule pages

Atovaquone API Clindamycin API

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $260K 1
2025 Not reported $1.0M 2

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Alchymars ICM SM comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was OAI, on 4 December 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts